Eone Diagnomics Genome CenterEDGC

Eone Diagnomics remains loss-making at the operating line and is going through a rehabilitation and leadership change, though its latest half-year profit figure is driven by non-operating items.

Eone Diagnomics Genome Center (EDGC) is a KOSDAQ-listed genome testing company whose revenue has fallen sharply, from ₩94B in 2022 to ₩6.3B on a trailing twelve-month basis to H1 2026. Recent filings center on rehabilitation proceedings, a rehabilitation plan approval, a CEO change and a partial lifting of an investment caution designation. The data does not include news headlines or any forecasts.

What stands out

• Trailing twelve-month revenue is ₩6.3B against an operating loss of ₩2.8B, an operating margin of -44.2%.
• Trailing net income of ₩43.7B is far above operating income, so the reported profit is not coming from core operations; the data does not explain the source.
• Trailing free cash flow is -₩15.4B, and cash is ₩11.5B with no borrowings.
• Filings show a rehabilitation plan approved on 26 August 2026 and an application to terminate rehabilitation proceedings the same day.
• The stock closed at ₩741 with a market cap of about ₩167B, and its 52-week high and low figures are not available in the data.

What to watch

• Whether the application to terminate rehabilitation proceedings is granted and what the rehabilitation plan requires going forward.
• Status of the partial lifting of the investment caution designation, which the August 14 notice says has no market measures yet.
• Effects of the CEO change and the earlier change of largest shareholder on business direction; the data does not include any guidance or analyst views.